{"title":"山奈酚通过CDK1泛素化在HCC细胞中引发细胞衰老。","authors":"Damin Liang, Min Tian, Guomei Hu, Yu Zhang, Lunyou Zhang, Juqi Chen, Xin Shen, Huayong Jian, Peng Tian, Tingchao Li, Xiaoju Cheng","doi":"10.1186/s12935-025-03961-1","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis. Cellular senescence, a state linked to cell cycle arrest, represents a potential therapeutic strategy for cancer. However, the clinical impact and regulatory mechanism of cellular senescence in HCC remains incompletely unknown. We identified HCC associated differentially expressed genes (DEGs) using bioinformatics analysis of public databases (TCGA, GEO, GEPIA, etc.). Enrichment, prognostic, risk scoring models analyses revealed cyclin-dependent kinase 1 (CDK1) as a core senescence-related gene. CDK1 expression was upregulated in HCC tissues and correlated with poor prognosis of HCC patients. In addition, CDK1 knockdown significantly increased senescence markers (the level or activity of P16, P21, and SA-β-gal), and induced cellular senescence in HepG2 cells. Molecular docking demonstrated high-affinity binding between CDK1 and kaempferol (KAE; affinity = -9.7 kcal/mol). KAE treatment similarly increased senescence markers and promoted cellular senescence in HepG2 cells. Mechanistically, KAE reduced CDK1 protein levels by promoting its ubiquitination and subsequent degradation. These findings indicated that KAE might induce cellular senescence through CDK1 ubiquitination, providing potential drugs and targets for HCC treatment.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"325"},"PeriodicalIF":6.0000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495675/pdf/","citationCount":"0","resultStr":"{\"title\":\"Kaempferol triggers cellular senescence via CDK1 ubiquitination in HCC cells.\",\"authors\":\"Damin Liang, Min Tian, Guomei Hu, Yu Zhang, Lunyou Zhang, Juqi Chen, Xin Shen, Huayong Jian, Peng Tian, Tingchao Li, Xiaoju Cheng\",\"doi\":\"10.1186/s12935-025-03961-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis. Cellular senescence, a state linked to cell cycle arrest, represents a potential therapeutic strategy for cancer. However, the clinical impact and regulatory mechanism of cellular senescence in HCC remains incompletely unknown. We identified HCC associated differentially expressed genes (DEGs) using bioinformatics analysis of public databases (TCGA, GEO, GEPIA, etc.). Enrichment, prognostic, risk scoring models analyses revealed cyclin-dependent kinase 1 (CDK1) as a core senescence-related gene. CDK1 expression was upregulated in HCC tissues and correlated with poor prognosis of HCC patients. In addition, CDK1 knockdown significantly increased senescence markers (the level or activity of P16, P21, and SA-β-gal), and induced cellular senescence in HepG2 cells. Molecular docking demonstrated high-affinity binding between CDK1 and kaempferol (KAE; affinity = -9.7 kcal/mol). KAE treatment similarly increased senescence markers and promoted cellular senescence in HepG2 cells. Mechanistically, KAE reduced CDK1 protein levels by promoting its ubiquitination and subsequent degradation. These findings indicated that KAE might induce cellular senescence through CDK1 ubiquitination, providing potential drugs and targets for HCC treatment.</p>\",\"PeriodicalId\":9385,\"journal\":{\"name\":\"Cancer Cell International\",\"volume\":\"25 1\",\"pages\":\"325\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495675/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12935-025-03961-1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03961-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Kaempferol triggers cellular senescence via CDK1 ubiquitination in HCC cells.
Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis. Cellular senescence, a state linked to cell cycle arrest, represents a potential therapeutic strategy for cancer. However, the clinical impact and regulatory mechanism of cellular senescence in HCC remains incompletely unknown. We identified HCC associated differentially expressed genes (DEGs) using bioinformatics analysis of public databases (TCGA, GEO, GEPIA, etc.). Enrichment, prognostic, risk scoring models analyses revealed cyclin-dependent kinase 1 (CDK1) as a core senescence-related gene. CDK1 expression was upregulated in HCC tissues and correlated with poor prognosis of HCC patients. In addition, CDK1 knockdown significantly increased senescence markers (the level or activity of P16, P21, and SA-β-gal), and induced cellular senescence in HepG2 cells. Molecular docking demonstrated high-affinity binding between CDK1 and kaempferol (KAE; affinity = -9.7 kcal/mol). KAE treatment similarly increased senescence markers and promoted cellular senescence in HepG2 cells. Mechanistically, KAE reduced CDK1 protein levels by promoting its ubiquitination and subsequent degradation. These findings indicated that KAE might induce cellular senescence through CDK1 ubiquitination, providing potential drugs and targets for HCC treatment.
期刊介绍:
Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques.
The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors.
Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.